Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity
Execs Shared Strategy At J.P. Morgan Meeting
Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.
